ArticleFrontiers in medicine2026
Macular Telangiectasia type 1 treated with integrated traditional Chinese acupuncture and Conbercept: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Macular Telangiectasia type 1 is a congenital vascular disorder primarily affecting males, characterized by unilateral exudative lesions on the temporal macula. Intravitreal anti-VEGF therapy is commonly used, but the response can be suboptimal in some patients. In this case, we report the management of Macular Telangiectasia type 1 using a integration of intravitreal anti-VEGF therapy and traditional Chinese acupuncture. Case presentation: A 38-year-old male presented with progressive vision loss and metamorphopsia in his right eye. Fundus examination and multimodal imaging (OCT/OCTA and fluorescein angiography) identified a perimacular hard exudate ring, cystoid macular edema, and juxtafoveal telangiectasis, consistent with idiopathic Macular Telangiectasia type 1. For the intervention, the patient received a total of three intravitreal Conbercept injections administered once monthly, integrated with peri-treatment acupuncture at predefined acupoints. Four months after the last treatment, the patient exhibited both visual and anatomical improvement. Conclusion: The integration of traditional Chinese acupuncture with Conbercept may offer therapeutic benefits for Macular Telangiectasia type 1 in this patient. Clinically meaningful improvements were observed, including improved visual acuity, reduced metamorphopsia, and decreased central retinal thickness over follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.